发明名称 |
PROGNOSE DES VERLAUFS EINER KREBSERKRANKUNG |
摘要 |
Method of determining a likelihood of cancer relapse in a subject who has completed cancer tumor surgery, radiotherapy treatment and/or chemotherapy treatment comprises contacting an antibody that binds specifically to a serum form of thymidine kinase 1 (STK1) protein with a blood serum sample one to six months after completing the surgery and/or treatment, and before any cancer relapse has been detected; determining an amount of antibody binding to STK1 protein in the sample; correlating the amount of antibody binding to STK1 protein to a concentration of STK1 protein in the sample; and based on the concentration of STK1 protein in the sample, generating decision support information representative of a likelihood of cancer relapse in the subject one to ten years after completion of the surgery and/or treatment, the decision support information comprising a likelihood value defining one of a high or low likelihood of cancer relapse. |
申请公布号 |
AT481644(T) |
申请公布日期 |
2010.10.15 |
申请号 |
AT20040733219T |
申请日期 |
2004.05.14 |
申请人 |
AROCELL AB |
发明人 |
SKOG, SVEN;ERIKSSON, STAFFAN;TRIBUKAIT, BERNHARD;HE, QIMIN |
分类号 |
G01N33/574;A61B;C12Q1/48;G01N33/573 |
主分类号 |
G01N33/574 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|